MannKind Scores Sanofi As A Partner For Afrezza – But At A Price
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi appears to be an ideal match to sell MannKind’s inhaled insulin Afrezza, but the terms of the exclusive worldwide licensing agreement for the product reflect its high-risk nature.
You may also be interested in...
INTERVIEW: Novo Downplays Afrezza, Pins Hopes On Oral Pipeline
Novo Nordisk appears not to be worried about any market impact from Afrezza, MannKind’s recently approved inhalable insulin. In an exclusive interview in Copenhagen, the Danish company’s leadership told PharmAsia News that it had taken sufficient steps to maintain its stronghold on the global insulin market.
Afrezza Approval Comes With Post-Marketing Trial On Lung Cancer, CV Risk
FDA’s unusually specific request suggests continued worries about safety of MannKind’s inhalable insulin; large trial (8,000-10,000 type 2 diabetics) has a variety of goals.
Afrezza Launch Waits On Marketing Partner; MannKind Ramps Up Production
Production of insulin powder inhaler cartridges at Connecticut facility will triple to 400 million a year by launch, which firm expects in 2015.